✦ LIBER ✦

Expression of fragile histidine triad and p53 in non-small cell lung cancer

✍ Scribed by Xing-hua Hou; Dao-rong Zhang

Publisher: Chinese Anti-Cancer Association
Year: 2006
Tongue: English
Weight: 628 KB
Volume: 18
Category: Article
ISSN: 1000-9604
DOI: 10.1007/s11670-006-0121-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Down-regulation of fragile histidine tri

Down-regulation of fragile histidine triad expression in prostate carcinoma

✍ Rebecca L. Fouts; George E. Sandusky; Shaobo Zhang; George J. Eckert; Michael O. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

## Background: The fragile histidine triad (fhit) gene is a tumor suppressor gene that belongs to the histidine triad family of nucleoside binding proteins. the gene encompasses the common human chromosomal fragile site, the fra3b locus at chromosome 3p14.2, and is expressed in most normal adult ti

The expressions and clinical significanc

The expressions and clinical significance of P53, C-erbB-2 and VEGF in non-small cell lung cancer

✍ Aiqin Gu; Yu Xin; Gang Chen; Baohui Han; Hao Ji; Bo Yan 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 77 KB

Fragile histidine triad gene expression

Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model

✍ Guo, Zongyou; Johansson, Sonny L.; Rhim, Johng S.; Vishwanatha, Jamboor K. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 610 KB

## BACKGROUND. The fragile histidine triad (FHIT) is frequently deleted and altered in many human cancers. Replacement of the FHIT gene into cancer cell lines lacking FHIT expression results in loss of tumorigenicity and tumor growth. METHODS. We investigated the status and function of the FHIT gen

p53tumour-suppressor gene in non-small-c

p53tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy

✍ K. Junker; T. Wiethege; K.-M. Müller; M. Thomas 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 184 KB

Quantitative analysis of p53 protein in

Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value

✍ Michael A. Levesque; Mario D'Costa; Ernest H. Spratt; Mohammad M. Yaman; Elefthe 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 99 KB 👁 2 views

Accumulation of mutant p53 protein occurs frequently in human malignancies, including 40-60% of non-small cell lung carcinomas. The implications of such p53 over-expression, usually assessed by immunohistochemical techniques, for the prognosis of lung cancer patients remain undetermined. In this stu

Analysis of p53 mutations in histologica

Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients

✍ Weimin Gao; Hussam H. Mady; Mona F. Melhem; Phouthone Keohavong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract Our previous study showed a characteristic p53 mutational spectrum in lung tumors from lung cancer patients in the Western Pennsylvania region. To further understand the involvement of p53 mutations in lung tumor development, in this study we compared p53 mutational spectra and distribu